DHHT Law Firm assists Tianchen Biotechnology in listing on the main board of the Hong Kong Stock Exchange
On June 5, 2026, Tianchen Biopharmaceutical (Suzhou) Co., Ltd. (referred to as Tianchen Biopharmaceutical, stock code 01779) made its initial public offering of H shares and listed on the main board of the Hong Kong Stock Exchange, joining the ranks of innovative pharmaceutical companies listed in the international capital market.
DHHT Law Firm has been appointed as the special legal advisor for project data compliance. Leveraging its professional strength in the fields of listing and data compliance, it provides legal services throughout the process. This special project was led by partner Li Shengnan from DHHT Law Firm's Shanghai office and lawyer Duan Yijing from the Shanghai office. The team, based on the business model of biologic innovative drugs and the characteristics of data flow, conducted data compliance due diligence, implemented compliance gap analysis and promoted the implementation of rectification, and issued legal opinions on data compliance within China. They also assisted the client in responding to the feedback from the China Securities Regulatory Commission and helped reply to relevant inquiries from overseas regulatory authorities and stock exchanges regarding data compliance matters within China during the overseas listing process. With professional data compliance services, DHHT Law Firm supports the capital market development of biotech enterprises and helps them successfully go public.
The total number of H shares issued globally by Tianchen Biotechnology this time is 14,193,150 shares. The price per share is set at 96.06 Hong Kong dollars. The total amount of funds raised is approximately 1.363 billion Hong Kong dollars, with the net amount raised being approximately 1.255 billion Hong Kong dollars. The public offering portion received 4,762.58 times of subscription.
Tianchen Biotech is an innovative biopharmaceutical company, dedicated to the research, production and commercialization of cutting-edge antibody drugs and biological products. It also focuses on immune, inflammatory and tumor diseases, and has established diverse research pipelines such as monoclonal antibodies, bispecific antibodies and antibody-drug conjugates (ADCs). With an innovative and efficient self-developed antibody research platform, several core products have entered clinical trials and industrialization, demonstrating outstanding innovation-driven momentum.
Tianchen Biotechnology successfully listed on the main board of the Hong Kong Stock Exchange, demonstrating the company's scientific and technological innovation capabilities, and also confirming the professional capabilities of DHHT Law Firm in the fields of biomedicine, listing, and data compliance. In the future, DHHT Law Firm will continue to uphold the concepts of "diligence, craftsmanship, and excellence", and provide diversified and customized legal services to accompany more Chinese enterprises to steadily and far-reaching development in the international capital market.
